⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27809794 | 0.69 | — | — | |
| SCHEMBL31280321 | 0.67 | — | — | |
| SCHEMBL7041041 | 0.65 | — | — | |
| SCHEMBL13806408 | 0.65 | — | — | |
| SCHEMBL9352627 | 0.64 | — | — | |
| SCHEMBL163782 | 0.61 | — | — | |
| SCHEMBL2124536 | 0.59 | MEN1 (0.30) | — | |
| SCHEMBL28308797 | 0.59 | — | — | |
| SCHEMBL30927080 | 0.59 | — | — | |
| SCHEMBL5661718 | 0.58 | PKM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2914253-B1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANTBIOSCIENCE INC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170135992-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2017-05-18 | — | — | US | disclosed |
| US-9499539-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANTBIOSCIENCE, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| EP-2914253-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | Nant Holdings IP, LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2086982-A1 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |